...

首页> 外文期刊>European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology >Long-term efficacy of lurasidone in antipsychotic-naive vs. antipsychotic-exposed adolescents with schizophrenia: Post-hoc analysis of a two year, open-label study

【24h】

Long-term efficacy of lurasidone in antipsychotic-naive vs. antipsychotic-exposed adolescents with schizophrenia: Post-hoc analysis of a two year, open-label study

机译：抗透视性幼稚与精神分裂症的抗精神病药幼虫的长期疗效：两年后的HOC分析，开放标签研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology》 |2019年第s6期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term efficacy of lurasidone in antipsychotic-naive vs. antipsychotic-exposed adolescents with schizophrenia: Post-hoc analysis of a two year, open-label study [J] . European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology . 2019,第S6期

机译：抗透视性幼稚与精神分裂症的抗精神病药幼虫的长期疗效：两年后的HOC分析，开放标签研究
2. 2.5 Efficacy and Safety of Lurasidone in Adolescents With Schizophrenia: Results of a Two-Year Open-Label Extension Study [J] . Robert S. Goldman, Michael Tocco, Andrei A. Pikalov, Journal of the American Academy of Child and Adolescent Psychiatry . 2018,第10期

机译：2.5含有精神分裂症的青少年酮的疗效和安全性：两年开放标签扩展研究的结果
3. 2.5 Efficacy and Safety of Lurasidone in Adolescents With Schizophrenia: Results of a Two-Year Open-Label Extension Study [J] . Robert S. Goldman, Michael Tocco, Andrei A. Pikalov, Journal of the American Academy of Child and Adolescent Psychiatry . 2018,第10期

机译：2.5含有精神分裂症的青少年酮的疗效和安全性：两年开放标签扩展研究的结果
4. High-level music exposure and hearing effects in adolescents: third year of a long-term study [C] . M.R. Serra, E.C. Biassoni, U. Richter, The 2001 International Congress and Exhibition on Noise Control Engineering Vol.3, 2001, Aug 27-30, 2001, The Hague, the Netherlands . 2001

机译：青少年的高水平音乐暴露和听力影响：长期研究的第三年
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. F106. EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAïVE ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 6-WEEK RANDOMIZED PLACEBO-CONTROLLED STUDY [O] . Christoph Correll, Robert Goldman, Michael Tocco, 2019

机译：F106。抗精神分裂症纯净青少年精神分裂症患者中卢拉西酮的疗效：6周随机化地点控制的研究的事后分析
7. 104 Long-term Efficacy of Lurasidone in Antipsychotic-naïve vs. Antipsychotic-exposed Adolescents with Schizophrenia: Analysis of a Two-Year Study [O] . Christoph U. Correll, Robert Goldman, Michael Tocco, 2020

机译：104抗透视性 - 幼稚酮与精神分裂症的抗精神病药暴露青少年的长期疗效：分析为期两年的研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号